Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Better Buy in 2026: Novo Nordisk or Intuitive Surgical?
06:45am, Thursday, 18'th Dec 2025
Novo Nordisk's new indications for semaglutide and its attractive pipeline could allow it to bounce back. Intuitive Surgical should remain the leader in its niche despite increased competition.
Bryan Johnson Says Human Immortality Could Be Possible By 2039 Thanks To AI Boom: 'Absolutely Insane Moment...'
05:26am, Thursday, 18'th Dec 2025
Bryan Johnson predicts immortality achievable in 14 years, but warns of risks in using AI and biotech. He says anti-aging therapies are still unsafe.
Country Club Bank Grows Holdings in Novo Nordisk A/S $NVO
05:16am, Thursday, 18'th Dec 2025
Country Club Bank boosted its holdings in shares of Novo Nordisk A/S (NYSE: NVO) by 83.0% during the undefined quarter, according to its most recent 13F filing with the SEC. The fund owned 49,360 shar
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk
03:50am, Thursday, 18'th Dec 2025
These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year.
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
06:45pm, Wednesday, 17'th Dec 2025
Novo Nordisk (NVO) closed at $47.81 in the latest trading session, marking a -2.35% move from the prior day.
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
02:29pm, Tuesday, 16'th Dec 2025
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars
06:48am, Tuesday, 16'th Dec 2025
Novo Nordisk A/S (NYSE: NVO) stock has plunged around 41% year to date, as per data from Benzinga Pro.
Novo Nordisk A/S $NVO Shares Sold by Corient Private Wealth LLC
05:32am, Tuesday, 16'th Dec 2025
Corient Private Wealth LLC cut its stake in shares of Novo Nordisk A/S (NYSE: NVO) by 6.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchang
Final Trade: JNJ, NVO, UBER, BMY
06:22pm, Monday, 15'th Dec 2025
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
11:36am, Monday, 15'th Dec 2025
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
10:01am, Monday, 15'th Dec 2025
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
2 Predictions for Novo Nordisk in 2026
09:30am, Sunday, 14'th Dec 2025
Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026.
European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy
01:55pm, Friday, 12'th Dec 2025
EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in the U.S., U.K., and other markets.
Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound
01:52pm, Friday, 12'th Dec 2025
Novo Nordisk (NVO) said its high-dose version of Wegovy has received a positive recommendation from the European Union's drug advisory board, potentially openin
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
11:40am, Friday, 12'th Dec 2025
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
